Antipsychotic-induced hyperprolactinaemia: case studies and review

Mittal, Shweta; Prasad, Suveera; Ghosh, Adwaita

doi:10.1136/postgradmedj-2017-135221

Cited by 9 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1 B), which is in agreement with previous reports 15 , 30 , 31 . Elevated PRL may be associated with antipsychotic use in schizophrenia patients 14 , 15 , 32 , which results from the blocking effect of antipsychotic drugs on DA2 receptors in the anterior pituitary, but the effect of antipsychotic drugs on PRL levels is related to the mechanism of action of different kinds of drugs 33 , 34 .…”

Section: Discussionmentioning

confidence: 99%

Altered levels of BMD, PRL, BAP and TRACP-5b in male chronic patients with schizophrenia

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Bone mineral density (BMD) has been found to decrease in schizophrenia patients. We examined BMD and the levels of prolactin (PRL), bone alkaline phosphatase (BAP) and tartrate resistant acid phosphatase isoform 5b (TRACP-5b) in male chronic schizophrenia patients and compared them with healthy controls in a Chinese Han population, which has not been reported before. Male patients with chronic schizophrenia (SPs; n = 79) and healthy controls (HCs; n = 56) were recruited. BMD and plasma PRL, BAP and TRACP-5b levels were measured and compared between the two groups. The SPs group was further divided into two subgroups: the elevated PRL group (PRL ≥ 25 ng/ml, EPRL; n = 38) and the normal PRL group (PRL < 25 ng/ml, NPRL; n = 41) in accordance with PRL levels. The levels of BAP and TRACP-5b were measured using sandwich enzyme-linked immunosorbent assay (ELISA) while serum PRL was measured with an Access Immunoassay Analyzer. BMD was determined by quantitative computed tomography. BMD levels significantly decreased and serum PRL and TRACP-5b levels were significantly higher in male chronic schizophrenia patients. The EPRL group had remarkably lower BMD and BAP level and higher TRACP-5b levels compared with the NPRL group and HCs. Moreover, there was a negative correlation between BMD and TRACP-5b in the EPRL group. We found that BMD, BAP and TRACP-5b levels in the EPRL group were significantly different than HCs and the NPRL group. PRL levels in schizophrenia patients may be related to BMD and bone metabolism. Monitoring BMD and markers of bone metabolism in clinical practice may therefore be helpful to understand the bone health status of schizophrenia patients. Osteoporosis is a metabolic bone disease characterized by reduction of bone mass and deterioration of skeletal tissues as well as abnormal bone metabolism 1. Patients with osteoporosis have an increased bone fragility and are prone to fractures 2. Osteoporosis can endanger human health and affect the quality of life 3. Adolescence is a critical period of bone accumulation, and the peak bone mass during this period is influenced by genetics, length of adolescence, and light exposure and other factors 1,2,4. Although genetically influenced, BMD is also influenced by various other factors including age, alcohol intake, smoking, nutrition, drug use, deficiency of vitamin D and various diseases 1,2,5-8. Research has found that the risk of osteoporosis and femoral neck fracture in schizophrenia is higher than that of the general population 3,9,10. In addition to lack of physical activity, smoking and drinking alcohol, poor nutrition and lack of sunshine, one of the primary reasons that schizophrenia patients are more likely to develop osteoporosis is long-term use of antipsychotics 11,12. Previous studies showed that use of antipsychotics has been associated with hyperprolactinemia (HPRL) and that PRL abnormality can affect metabolic and reproductive functions and endocrine systems in vivo 13,14. HPRL influences bone metabolism by inhibiting the hypothalamus-pituita...

show abstract

Section: Discussionmentioning

confidence: 99%

Altered levels of BMD, PRL, BAP and TRACP-5b in male chronic patients with schizophrenia

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…При этом психические заболевания обычно предполагают длительное лечение. Так, для достижения антипсихотического или антидепрессивного эффекта требуется несколько недель, что существенно увеличивает риск развития нежелательных побочных эффектов, которые включают в себя экстрапирамидные расстройства с дальнейшим развитием поздней дискинезии [5], гиперпролактинемию [6], удлинение интервала QT и желудочковую тахикардию по типу пируэт [7], гематотоксичность [8], метаболические нарушения [9]. В связи с этим очень важное значение имеет предупреждение нерационального назначения лекарственных препаратов, риск от применения которых может превышать пользу у пациентов пожилого возраста.…”

unclassified

Safety of pharmacotherapy in the elderly patients with psychiatric diseases

Kirilochev¹,

Умерова²,

Дорфман³

et al. 2020

CPT

View full text Add to dashboard Cite

аспекты безопасности фармако тера пии пожилых пациентов с психическими заболеваниями. Клин фармакол тер 2020;29(1):80-84 [Kirilochev OO, Umerova AR, Dorfman IP, Bataeva SE. Safety of pharmacotherapy in the elderly patients with psychiatric diseases. Klinicheskaya farmakologiya i terapiya = Clin Pharmacol Ther 2020;29(1). (In Russ.)].

show abstract